RN486, a Bruton’s tyrosine kinase (BTK) inhibitor, has been shown to antagonize ABCG2-mediated resistance in preclinical models, enhancing drug retention in ABCG2-overexpressing cancer cells [42]. Here, BTK is linked to cancer.